Price Alert

Seres Therapeutics Inc. (MCRB)

NASDAQ: MCRB · Real-Time Price · USD

19.04

0.24 (1.28%)

At close: Sep 05, 2025, 11:29 AM

1.28% (1D)

Bid	18.96
Market Cap	166.69M
Revenue (ttm)	5.96M
Net Income (ttm)	85.97M
EPS (ttm)	-6.9
PE Ratio (ttm)	-2.76
Forward PE	-1.82
Analyst	Hold

Ask	19.28
Volume	16,577
Avg. Volume (20D)	126,143
Open	18.64
Previous Close	18.80
Day's Range	18.60 - 19.34
52-Week Range	6.53 - 26.40
Beta	2.89

About MCRB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MCRB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MCRB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Seres Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-10.54%

Seres Therapeutics shares are trading lower follow... Unlock content with Pro Subscription

3 months ago

-16.04%

Seres Therapeutics shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.

News

1 week ago · zacks.com

Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross

After reaching an important support level, Seres Therapeutics, Inc. (MCRB) could be a good stock pick from a technical perspective. MCRB recently experienced a "golden cross" event, which saw its 50-d...

4 weeks ago · seekingalpha.com

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Carlo Tanzi - Corporate Participant Investor Relations - Corporate Participant D...

4 weeks ago · fool.com

Seres (MCRB) Q2 Loss Narrows 34%

1 month ago · seekingalpha.com

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Seres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce ...